Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study

Breast Cancer Research and Treatment

Volumn 135, Issue 3, 2012, Pages 875-883

  Kaufman, Peter A ^a   Brufsky, Adam M ^b   Mayer, Musa ^c   Rugo, Hope S ^d   Tripathy, Debu ^e   Yood, Marianne Ulcickas ^f,g   Feng, Shibao ^h   Wang, Lisa I ^h   Quah, Cheng S ^h   Yardley, Denise A ⁱ  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c Patient Advocate   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f EpiSource LLC   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GENENTECH INC   (United States)

ⁱ SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer; Elderly; HER2 positive; Observational; Survival; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER REGISTRY; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84866528848     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2209-z     Document Type: Article

References (30)

1. Balducci L, Phillips DM (1998) Breast cancer in older women. Am Fam Physician 58:1163-1172 (Pubitemid 28469042)
2. Downey L, Livingston R, Stopeck A (2007) Diagnosing and treating breast cancer in elderly women: a call for improved understanding. J Am Geriatr Soc 55:1636-1644 (Pubitemid 47508503)
3. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer Am, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winder EP, CALGB Investigators (2009) Adjuvant chemotherapy in older women with earlystage breast cancer. N Engl J Med 360:2055-2065
4. Crivellari D, Aapro M, Leonard R, von Minckwitz G, Brain E, Goldhirsch A, Veronesi A, Muss H (2007) Breast cancer in the elderly. J Clin Oncol 25:1882-1890 (Pubitemid 46854422)
5. Pallis AG, Fortpied C, Wedding U, Van Nes MC, Penninckx B, Ring A, Lacombe D, Monfardini S, Scalliet P, Wildiers H (2012) EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 46:1502-1513
6. Talarico L, Chen G, Pazdur R (2004) Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 22:4626-4631 (Pubitemid 41185131)
7. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067 (Pubitemid 30035956)
8. Townsley CA, Selby R, Siu LL (2005) Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23:3112-3124 (Pubitemid 46224135)
9. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808-3815 (Pubitemid 47477254)
10. Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, Reed M, Ciatto S, Voogd AC, Brain E, Cutuli B, Terret C, Gosney M, Aapro M, Audisio R (2012) Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13:e148-e160
11. Du X, Goodwin JS (2001) Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol 19:1455-1461 (Pubitemid 32202553)
12. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885-892 (Pubitemid 32171549)
13. Townsley C, Pond GR, Peloza B, Kok J, Naidoo K, Dale D, Herbert C, Holowaty E, Straus S, Siu LL (2005) Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol 23:3802-3810
14. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schäfer P, Kurtz J, Sappino AP, Vlastos G (2003) Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21:3580-3587 (Pubitemid 46594049)
15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182 (Pubitemid 17231334)
16. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ (1991) Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655
17. Estevez L, Seidman A (2003) HER2-positive breast cancer: incidence, prognosis, and treatment options. Am J Cancer 2:169-179 (Pubitemid 36876615)
18. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA (2011) Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 14:4834-4843
19. National Cancer Institute (2006) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocol Development/electronic- applications/docs/ctcaev3.pdf. Accessed May 9, 2012
20. Monfardini S, Yancik R (1993) Cancer in the elderly: meeting the challenge of an aging population. J Natl Cancer Inst 85:532-538 (Pubitemid 23110926)
21. Du XL, Xia R, Burau K, Liu C-C (2005) Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005. Med Oncol 28:S80-S90
22. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238
23. Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, Baselga J, Di Cosimo S (2012) Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 23:897-902
24. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database of Syst Rev 4:CD006243
25. Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, Lestuzzi C, Maurea N, Oliva S, Russo G, Faggiano P, Italian Cardio-Oncologic Network (2012) Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 18:113-119
26. Griffiths RI, Lalla D, Herbert RJ, Doan JF, Brammer MG, Danese MD (2011) Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. Cancer Invest 29:573-584
27. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R (2006) Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107:696-704 (Pubitemid 44232661)
28. Pienkowski T, Zielinski CC (2010) Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Ann Oncol 21:917-924
29. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792 (Pubitemid 32222155)
30. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265-4274 (Pubitemid 46207001)